Evaluation and comparison of the safety and effectiveness of Intra uterine injection of autologous menstrual blood-derived stem cells (MenSCs) and PRP in unfertilized women with thin unfunctional endometrium

Evaluation and comparison of the safety and effectiveness of intra utrine injection of autologous menstrual blood-derived stem cells (MenSCs) and PRP in unfertilized women with thin unfunctional endometrium

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180619040147N3

Enrollment

Registered

2020-05-19

Start date

2020-05-21

Completion date

Unknown

Last updated

2020-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

thin endometrium. Abnormal findings on diagnostic imaging of urinary organs

Interventions

Intervention 1: Intervention group: includes 18 patients with thin endometrium that will be treated by once injection of autologous menstrual blood stem cells. After cells isolation, culture, and qua

Eligibility

Sex/Gender

Female

Age

25 Years to 40 Years

Inclusion criteria

Inclusion criteria: married women under 7 mm thickness of endometrium showing 3-4 Appelbaum classification of endometrium tissue pattern minimum or no blood supply of zone 3 of endometrium score 1-0 of arterial blood flow into endometrium intrauterine adhesions a history of no responding to routine treatment for this issue having at least 2 high quality embryos in freeze cycle ages between 25-40

Exclusion criteria

Exclusion criteria: Thyroid disfunction Immune disorders history of cancer, chemotherapy and radiotherapy hepatitis B, C and HIV infections severe endometriosis diabetes Dysfunction of electrolyte or liver tests

Design outcomes

Primary

Measure	Time frame
Endometrium thickness. Timepoint: 1, 2 and 3rd month after injection. Method of measurement: Vaginal sonography.;Uterine arterial blood flow. Timepoint: 1, 2 and 3rd month after injection. Method of measurement: Vaginal sonography.;Blood flow precence into zone 3 of the endometrium. Timepoint: 1, 2 and 3rd month after injection. Method of measurement: vaginal sonography.;Endomtrial tissue pattern. Timepoint: 1, 2 and 3rd month after injection. Method of measurement: vaginal sonography.	—

Measure

Time frame

Endometrium thickness. Timepoint: 1, 2 and 3rd month after injection. Method of measurement: Vaginal sonography.;Uterine arterial blood flow. Timepoint: 1, 2 and 3rd month after injection. Method of measurement: Vaginal sonography.;Blood flow precence into zone 3 of the endometrium. Timepoint: 1, 2 and 3rd month after injection. Method of measurement: vaginal sonography.;Endomtrial tissue pattern. Timepoint: 1, 2 and 3rd month after injection. Method of measurement: vaginal sonography.

—

Secondary

Measure	Time frame
Implantation rate. Timepoint: in new intra-cytoplasmic sperm injection cycle after intervention. Method of measurement: vaginal sonography.;Clinical pregnancy. Timepoint: 6-8 weeks after last menstrual period. Method of measurement: Vaginal sonography.;Live birth. Timepoint: 9 months after pregnancy. Method of measurement: delivery report based on gynecologist comment.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSomaieh Kazemnejad

Iranian academic center for education culture and research

kazemnejad_s@yahoo.com+98 21 2243 2020

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026